Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

National Institute for Health and Care Excellence NICE logo

Lilly’s Efient and Sucampo’s Amitiza win NICE backing

Blood clot and constipation drugs recommended for NHS use

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

National Institute for Health and Care Excellence NICE logo

NICE confirms wider statin use

Reduces threshold for risk of heart disease

- PMLiVE

Pfizer inks $360m deal to buy InnoPharma

Boosts position in the buoyant sterile injectables market

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Research Partnership

- PMLiVE

SMC decides Celgene’s Imnovid is not cost-effective

Scottish cancer patients denied access to the cancer drug

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

EU flag

Updated EMA reports better suited to HTA needs

Changes to drug licensing reports are helping to support reimbursement decisions

National Institute for Health and Care Excellence NICE logo

NICE backs constipation treatment

Sucampo’s Amitiza set for NHS use in England and Wales

UK flag

NICE guidelines on atrial fibrillation discourage aspirin use

Health watchdog encourages greater NHS use of new anticoagulant drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links